01 Increasing Preference for Personalized Therapies The growing use of personalized cell and gene therapies is driving the adoption of chain of identity packaging across the supply chain. Companies are using unique barcodes, RFID tags, and tamper-evident labels to ensure every therapy remains linked to the correct patient during storage and transportation. This improves product traceability, reduces the risk of product mix-ups, and supports regulatory compliance. For example, Thermo Fisher Scientific offers identification and labeling solutions that support the chain of identity and chain of custody for advanced therapies.
02 Increasing Adoption of Multi-Temperature Packaging Solutions The wider use of different cell and gene therapies is encouraging manufacturers to develop packaging that supports multiple temperature ranges. Companies are introducing packaging systems that protect therapies stored under refrigerated, frozen, and cryogenic conditions, allowing a single packaging portfolio to serve different treatment types. This improves logistics efficiency and helps maintain product quality during global distribution.
01 The cell and gene therapy packaging market is highly exposed to supply chain disruptions due to its reliance on specialized cryogenic packaging systems, validated cold chain materials, and temperature-controlled logistics for advanced therapies. Disruptions in the supply of insulated shippers, cryogenic containers, phase change materials, and qualified packaging components have affected production schedules, increased transportation costs, and delayed the global distribution of time-sensitive cell and gene therapies. The market is witnessing a capacity-constrained recovery, as demand for cell and gene therapy packaging remains strong while the availability of specialized packaging materials, qualified logistics capacity, and cryogenic infrastructure continues to limit the pace of market expansion.
01 The cell and gene therapy packaging market forecasts continued investment activity driven by the growing commercialization of cell and gene therapies, increasing demand for temperature-controlled packaging, and the need for reliable cold chain logistics.Key Investment and Funding Activities in Cell and Gene Therapy Packaging Market, 2025–2026 Company Funding/Investment (USD) Details Syntax Bio USD 14.4 Million In June 2026, the company closed an expanded Series A financing round (bringing total funding past USD 25 million) to advance its CRISPR-based Cellgorithm platform and a pancreatic beta cell therapy program targeting type 1 diabetes. Anocca USD 46 Million In August 2025, the company raised USD 46 million (approx. SEK 440 million) to advance the clinical development of its VIDAR-1 TCR-T cell therapy program targeting mutant KRAS in pancreatic cancer.
01 Commercial Therapy Approvals and Expansion of Cryogenic Logistics Networks Drive Market Commercial therapy approvals are driving demand for specialized cell and gene therapy packaging. In 2026, the US Food and Drug Administration (FDA) stated that its Center for Biologics Evaluation and Research (CBER) has approved close to 50 cell and gene therapies over the last decade, with approvals continuing in 2026. Each commercial therapy requires validated packaging to maintain product quality during storage and transportation. This is supporting the use of cryogenic packaging, insulated shippers, and temperature-controlled containers. For example, the FDA approved KRESLADI in 2026, requiring specialized cold chain distribution.Cryogenic logistics networks are supporting the safe distribution of temperature-sensitive cell and gene therapies. Reliable logistics providers require packaging that maintains ultra-low temperatures throughout transportation. This creates demand for insulated shippers, cryogenic containers, and validated thermal packaging solutions. Better logistics infrastructure also helps manufacturers deliver therapies across global treatment centers while maintaining product quality.
01 Strict Regulatory Validation Requirements and Limited Standardization of Packaging Systems Restrain Market Expansion Cell and gene therapy packaging must undergo extensive validation to demonstrate product safety, sterility, and temperature performance before commercial use. The validation process requires additional testing, documentation, and regulatory review, which increases development time and operational costs. This slows the introduction of new packaging solutions and delays their adoption across the market.Cell and gene therapies use different storage conditions, container formats, and handling requirements. Packaging manufacturers must develop customized solutions instead of standardized packaging for all therapies. This increases production complexity and costs, limiting large-scale adoption of packaging solutions.
01 Point of Care Manufacturing & Cell Banking Services Offer Growth Opportunities to Market Players Point of care manufacturing creates new opportunities for packaging companies supplying compact and easy-to-handle packaging solutions. Hospitals and healthcare providers require packaging that supports short-distance transportation, temporary storage, and safe handling of patient-specific therapies within medical facilities. This opens new business opportunities for manufacturers developing packaging for decentralized treatment models.Cell banking services create opportunities for manufacturers of cryogenic packaging and storage solutions. Biobanks, research institutes, and therapy developers require validated packaging to preserve and transport cellular materials under controlled conditions. This allows packaging companies to supply specialized containers for long-term storage and sample movement. In the future, the wider use of cell banking is expected to support demand for high-performance cryogenic packaging. For example, BioLife Solutions provides cryogenic storage and biopreservation solutions used by cell banking organizations.
01 Reverse Logistics Management and Product-Specific Packaging Requirements Challenge Growth Reusable packaging used for cell and gene therapies must be collected, inspected, and returned after each shipment. Managing these reverse logistics processes across multiple countries increases operational complexity and transportation costs. This reduces the efficiency of reusable packaging programs and slows their wider adoption.Each cell and gene therapy can have different storage temperatures, container formats, and handling procedures. Packaging manufacturers must manage multiple product-specific configurations instead of streamlined production. For example, autologous and allogeneic therapies often require different packaging formats, increasing manufacturing complexity and limiting operational efficiency.
July 2026 Repligen Corporation announced a merger agreement to acquire BioLife Solutions. The transaction expands Repligen's portfolio of biopreservation media, cell processing tools, and cold chain solutions.
May 2026 ThermoSafe announced the expansion of its US vacuum insulated panel (VIP) manufacturing capacity to strengthen the production of temperature-controlled packaging for pharmaceuticals, biologics, and cell and gene therapies.
February 2026 ThermoSafe launched Orion Express, a reusable temperature-controlled shipping solution designed for time-critical pharmaceutical shipments, including cell and gene therapy applications.